BCL2 and neoplasm: Senescent cells harbour vulnerabilities allowing their specific killing by various ‘senolytics’ [24, 119], including BCL‐2 and BCL‐xL inhibitors (venetoclax, navitoclax, A1331852, ...) that were observed to augment the tumour response to CDK4/6i [120, 121].